End-of-day quote
Nyse
03:30:00 04/06/2024 am IST
|
5-day change
|
1st Jan Change
|
39.19
USD
|
+2.62%
|
|
+1.42%
|
0.00%
|
Fiscal Period: December |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,782
|
-
|
-
|
Enterprise Value (EV)
1 |
8,325
|
8,174
|
7,973
|
P/E ratio
|
27.8
x
|
26.6
x
|
25
x
|
Yield
|
1.28%
|
1.36%
|
1.43%
|
Capitalization / Revenue
|
2.77
x
|
2.63
x
|
2.49
x
|
EV / Revenue
|
2.96
x
|
2.77
x
|
2.55
x
|
EV / EBITDA
|
13.2
x
|
11.7
x
|
10.5
x
|
EV / FCF
|
34.7
x
|
28.5
x
|
23.7
x
|
FCF Yield
|
2.88%
|
3.51%
|
4.23%
|
Price to Book
|
9.49
x
|
7.68
x
|
6.35
x
|
Nbr of stocks (in thousands)
|
2,00,004
|
-
|
-
|
Reference price
2 |
38.91
|
38.91
|
38.91
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,678
|
2,808
|
2,956
|
3,124
|
EBITDA
1 |
-
|
629.2
|
697
|
760.9
|
EBIT
1 |
-
|
442.5
|
478.4
|
509.3
|
Operating Margin
|
-
|
15.76%
|
16.19%
|
16.3%
|
Earnings before Tax (EBT)
1 |
-
|
380.5
|
420.5
|
446
|
Net income
1 |
260
|
281.6
|
292.7
|
309
|
Net margin
|
9.71%
|
10.03%
|
9.9%
|
9.89%
|
EPS
2 |
-
|
1.400
|
1.465
|
1.559
|
Free Cash Flow
1 |
-
|
239.9
|
287.3
|
337
|
FCF margin
|
-
|
8.54%
|
9.72%
|
10.79%
|
FCF Conversion (EBITDA)
|
-
|
38.13%
|
41.22%
|
44.29%
|
FCF Conversion (Net income)
|
-
|
85.18%
|
98.15%
|
109.05%
|
Dividend per Share
2 |
-
|
0.4992
|
0.5283
|
0.5581
|
Announcement Date
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
670
|
720.8
|
704.2
|
711.6
|
697.9
|
760.1
|
EBITDA
1 |
131
|
171.4
|
158.8
|
163.9
|
144.7
|
193.2
|
EBIT
1 |
90
|
123.3
|
110.7
|
114
|
93.94
|
136.9
|
Operating Margin
|
13.43%
|
17.1%
|
15.72%
|
16.02%
|
13.46%
|
18.02%
|
Earnings before Tax (EBT)
1 |
73
|
106.5
|
96
|
104
|
78.5
|
125.5
|
Net income
1 |
56
|
79.47
|
72.24
|
77.05
|
54
|
89
|
Net margin
|
8.36%
|
11.03%
|
10.26%
|
10.83%
|
7.74%
|
11.71%
|
EPS
2 |
0.2800
|
0.3854
|
0.3583
|
0.3755
|
0.2749
|
0.4388
|
Dividend per Share
2 |
0.1300
|
0.1275
|
0.1275
|
0.1275
|
0.1275
|
0.1275
|
Announcement Date
|
20/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
543
|
392
|
191
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.8623
x
|
0.5619
x
|
0.2514
x
|
Free Cash Flow
1 |
-
|
240
|
287
|
337
|
ROE (net income / shareholders' equity)
|
-
|
38%
|
33%
|
29.6%
|
ROA (Net income/ Total Assets)
|
-
|
10.2%
|
10.2%
|
10.6%
|
Assets
1 |
-
|
2,772
|
2,872
|
2,917
|
Book Value Per Share
2 |
-
|
4.100
|
5.070
|
6.130
|
Cash Flow per Share
2 |
-
|
2.180
|
2.730
|
-
|
Capex
1 |
-
|
234
|
243
|
246
|
Capex / Sales
|
-
|
8.32%
|
8.21%
|
7.89%
|
Announcement Date
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
38.91
USD Average target price
41.53
USD Spread / Average Target +6.73% Consensus |
1st Jan change
|
Capi.
|
---|
| 0.00% | 783.81Cr | | +13.87% | 1.74TCr | | -12.51% | 270.47Cr | | -20.14% | 261.88Cr | | -27.64% | 188.21Cr | | -11.99% | 106.07Cr | | -10.77% | 103.92Cr | | +1.19% | 84Cr | | -1.66% | 75Cr | | -23.33% | 73Cr |
Testing Laboratories
|